Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial to Determine Safety and Efficacy of Non Viral Allogeneic Dual CD123/33 Chimeric Antigen Receptor CIK (CARCIK CD123/33) Cells in Adult and Pediatric Patients With Relapse/Refractory Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

NCT07877610 is registered in ClinicalTrials.gov with Fondazione Matilde Tettamanti Menotti De Marchi Onlus as lead sponsor.

NCT NCT07877610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07877610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial to Determine Safety and Efficacy of Non Viral Allogeneic Dual CD123/33 Chimeric Antigen Receptor CIK (CARCIK CD123/33) Cells in Adult and Pediatric Patients With Relapse/Refractory Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Lead sponsor
Fondazione Matilde Tettamanti Menotti De Marchi Onlus
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 31, 2026
Completion date
October 31, 2029
Enrollment
18 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

aml (acute myeloid leukemia), bpdcn